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Abstract
Background: Large-scale clinical trials with thousands of participants are often needed to evaluate the risk
reductions of cardiac events and/or death. Many recent clinical trials have evaluated the incidences of cardiac
events using hard endpoints, especially in cardiovascular and metabolic medicine. A high investigation cost is
involved in conducting a large-scale clinical trial, and obtaining sufficient funding is essential. The infrastructural
environment of clinical trials is currently inadequate in Japan. We conducted a questionnaire-based survey to
address this issue. The present study sought to clarify the current situation surrounding large-scale clinical trials in
terms of funding and infrastructure, and to inform discussion about improving the financial and infrastructural
situation for clinical trials.
Methods: We sent questionnaires to 119 sponsors of large-scale clinical trials between August 2007 and December
2007, and between July 2009 and August 2009. Answers to each question were summarized and data were
statistically analyzed.
Results: We received responses from the sponsors of 63 (52.9%) out of 119 trials to which questionnaires were
sent. The results revealed that 25 trials (39.7%) were funded by foundations, and 21 trials (33.3%) were funded by
public agencies. All of the foundations involved in conducting clinical trials, where funding sources were specified,
were funded by private organizations such as pharmaceutical companies. All of the clinical trials with a cost of JPY
300 million (USD 3.27 million) or more were funded by private organizations, and none were funded solely by
public agencies. The sponsors of 23 trials (36.5%) responded that the trial was ‘not registered’ to clinical trial
registry.
Conclusions: The questionnaire responses revealed that there were still many trials whose funding sources were
unclear and many sponsors were unaware of their responsibilities in managing and/or financing the costs of
clinical trials. These findings indicate that further discussion is required to establish appropriate frameworks and/or
rules regarding funding, while considering conflicts of interest. This discussion should take place as soon as
possible to facilitate appropriate clinical trials.
Background
In the 1970s, researchers began to conduct large-scale
clinical trials in Western countries, with the incidence
of cardiovascular events as endpoints [1,2]. Although
large-scale clinical trials in Japan began approximately
10 years later than in Western countries, the number of
large-scale clinical trials has since increased. Recently, a
large number of clinical trials seeking to evaluate the
incidence of cardiac events and/or death using hard
endpoints have been conducted in cardiovascular and
metabolic medicine in Japan.
The Japanese Acute Myocardial Infarction Prospective
(JAMP) study [3] was the first non-pharmaceutical com-
pany-funded multicenter trial of a medication in Japan.
The JAMP study group concluded that there was no sig-
nificant improvement in outcomes associated with angio-
tensin-converting enzyme inhibitor administration in
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a Japanese study population.
After the JAMP study, we found a number of issues
surrounding large-scale clinical trials [4]. In particular, the
funding sources and infrastructure of clinical trials were
found to be major issues. Our results indicated that finan-
cial and infrastructural resources must be maintained to
adequately conduct clinical trials. However, a substantial
cost is involved, and obtaining funding is thus essential for
clinical trials. The infrastructural environment surround-
ing clinical trials is currently inadequate, although this
situation is improving. At present, Japanese clinical trials
are funded by various sources, including public agencies,
private companies, foundations, etc. Several studies have
reported that industry-funded trials potentially suffer from
biased results, interpretations and conclusions [5-11].
Ridker, et al. found that cardiovascular trials reported
between 2000 and 2005 that were funded by for-profit
organizations were more likely to report positive findings
than those funded by not-for-profit organizations [5].
Considering the current situation surrounding the medical
and pharmaceutical industries, as well as the situation for
researchers, it is unlikely that researchers can completely
avoid conflicts of interest. As such, the International Com-
mittee of Medical Journal Editors (ICMJE) requested in
2004 that sponsors disclose information regarding trial
management, including funding sources [12]. However, no
comprehensive regulations are currently in place to man-
age conflicts of interest in Japan.
In the current study, we conducted a survey among trial
sponsors, using questionnaires to elucidate the current
funding and infrastructural environment surrounding
large-scale clinical trials investigating cardiovascular dis-
eases in Japan. In this article, we report the results of our
survey regarding relevant issues surrounding large-scale
clinical trials for cardiovascular diseases in Japan.
Methods
We sent questionnaires to the sponsors of large-scale clin-
ical trials. A ‘sponsor’ was defined as ‘an individual, com-
pany, institution or organization that takes responsibility
for the initiation, management and/or financing of a clini-
cal trial’ [13-15]. We targeted our questionnaires to the
chairperson, or, when the sponsor was an institution or
organization, to the individual with the most responsibility
according to the official disclosure of the organization.
Between August 2007 and December 2007 we sent
questionnaires to 90 large-scale clinical trial programs
that commenced before February 2007. One-hundred
and seventeen trials were found by 1) PubMed, 2) Ichushi
(Japana Centra Revuo Medicina, URL: http://login.jamas.
or.jp/), 3) websites of related medical societies, 4) Univer-
sity Hospital Medical Information Network (UMIN)
Clinical Trials Registry (URL: http://www.umin.ac.jp/ctr/
index-j.htm), and 5) clinicaltrials.gov (URL: http://www.
clinicaltrials.gov/) on 25 February, 2007. Of 117 trials, we
found addresses of sponsors for 90 trials, and we sent
questionnaires to all sponsors whose addresses could be
identified. In addition, 35 more trials were found using
t h es a m ed a t as o u r c e sa sm e n t i o n e da b o v eo n2 5J u l y ,
2009. We found addresses for sponsors of 29 of these 35
trials, and, sent questionnaires to all sponsors whose
addresses could be identified between July 2009 and
August 2009.
We defined ‘large-scale clinical trials’ as trials where the
number of participants was 300 or more. If a trial was
ongoing beyond the cut-off date and its planned number
of participants was 300 or more, this trial was also
regarded as a ‘large-scale clinical trial’.W es o u g h tt o
include all large-scale clinical trials that examined cardio-
vascular and metabolism disease (i.e. cardiovascular, cer-
ebrovascular events, and/or death) and used true
endpoints as their primary endpoints. A true endpoint
was an endpoint involving cardiovascular events, such as
myocardial infarction, chronic heart failure, ischemic
heart attack, and/or death. We sent questionnaires to the
sponsors of all clinical trialst h a tm e tt h ea b o v ec r i t e r i a ,
except for sponsors that we did not have access to.
Our questionnaires consisted of categorical choices
(Additional file 1 Figure S1). Sponsors were asked to
return the questionnaires within 2 weeks, but all responses
were included in our analyses, regardless of when they
were returned. We analyzed all responses after checking
the accuracy and appropriateness of the data, without spe-
cifying the trial or each sponsor.
We presented mean, standard deviation, median and
IQR for the continuous variables, absolute numbers and
percentages for binary and categorical variables. The sta-
tistical tests were used for the comparisons between the
groups by funding source. P-values were calculated using
Kruskal-Wallis test, and p < 0.05 was considered to be
statistically significant. Data were statistically analyzed
using software (R version 2.13.1).
We did not obtain an ethical approval for this study,
because our study was not a medical research involving
human subjects to understand the causes, development
and effects of diseases and improve preventive, diagnos-
tic and therapeutic interventions.
Results
Numbers of participants in large-scale clinical trials to
which questionnaires were sent and those that answered
We sent questionnaires to sponsors of 119 large-scale clin-
ical trials. We received responses from 63 trials (52.9%). Of
the 90 trials to which questionnaires were sent in August
2007 - December 2007, we received responses from 53
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in July 2009 - August 2009, we received responses from 10
(34.5%).
The number of participants is summarized in Table 1.
Twenty-four of the 63 responding trials (38.1%) involved
less than 1,000 participants, 19 (30.2%) involved 1,000 -
2,999 participants, 15 (23.8%) involved 3,000 - 9,999
participants, and three (4.8%)i n v o l v e d1 0 , 0 0 0p a r t i c i -
pants or more. The results did not reveal clear differ-
ences in the numbers of participants between trials that
responded relative to all target trials.
Numbers of trials and participants by funding source
We calculated the numbers of large-scale clinical trials
per funding source.
Twenty-five trials (39.7%) were funded by foundations,
21 trials (33.3%) were funded by public agencies such as
the Ministry of Health, Labour, and Welfare (MHLW),
13 trials (20.6%) were funded by private organizations
such as pharmaceutical companies, and 10 trials (15.9%)
were self-funded. Sponsors of two trials (3.2%) reported
that their trials were funded by “others”, and the sponsor
of one trial (1.6%) reported that the funding source was
“unknown or unspecified”. For this question, the sum of
all frequencies did not equal 63 (100%), because multiple
answers were allowed. Of the 25 trials that were funded
by foundations, all trials except for those where funding
was unknown or unspecified were found to be funded by
private organizations (such as pharmaceutical companies)
through foundations.
The number of participants by funding source is sum-
marized in Table 2. In total, the mean number of partici-
pants was 2,582. The mean number of participants in
private funding and combined funding trials were 3,202
and 3,361, respectively. In publicly funded trials the
mean number was 1,348.
The number of large-scale clinical trials by total cost is
shown in Table 2. Nineteen trials (30.2%) where the cost
or estimated cost was JPY 100 - 300 million (i.e. USD 1.09
- 3.27 million, calculated based on the foreign exchange
rate on 20 February, 2010). Most of the trials were
categorized in this range. The second- and third-most
common cost categories were JPY 30 - 100 million (USD
0.33 - 1.09 million) and JPY 300 million - 1 billion (USD
3.27 - 10.9 million), respectively, with 10 trials (15.9%)
fitting into each of these categories. 58.1% of the trials (32
out of 55 answered trials) cost JPY 100 million (USD 1.09
million) or more.
Regarding the relationship between funding sources
and the cost of the trials, none of the clinical trials with a
cost of JPY 300 million (USD 3.27 million) or more were
funded solely by public agencies. The total trial costs
were significantly different between trials involving differ-
ent types of funding sources (p = 0.0003).
Eight trials (12.7%) responded that the source was
unknown or left the question unanswered.
In an additional question, we asked details of the cost to
the sponsors. The sponsors of 29 trials responded. Of
these, 18 trials were funded by private sources. Nine of the
29 sponsors answered this question. Of these 9 unan-
swered trials, 8 trials were funded by private sources. The
major reasons given for not answering were that the
details were ‘unknown’ because some of the responders
were not involved in cost management for their trials.
Party responsible for monitoring and data management
activities, and involvement of third-party
Regarding the infrastructure required for conducting
large-scale clinical trials, we investigated the situations sur-
rounding the support of human resources and material
resources in trials whose sponsors reported foundations or
private organizations as funding sources. Of 63 trials, 37
trials were private-funded. Nineteen of 37 trials (51.4%)
received human or material resources from other organi-
zations. Sixteen trials (43.2%) were supported with human
resources only, one trial (2.7%) was supported with mate-
rial resources only, and one trial (2.7%) was supported
with both human and material resources. Fifteen trials
(37.0%) were not supported with human or materials
resources, receiving only financial resources. Three trials
(8.1%) either reported that their support was unknown or
left the question unanswered.
Table 1 Numbers of participants involved in large-scale clinical trials to which questionnaires were sent, and number
of participants involved in trials that responded
Number of participants in clinical trial Responded trial*
n (%)
Not-responded trial*
n (%)
Total
†
n (%)
< 999 24 (38.1%) 28 (50.0%) 52 (43.7%)
1,000 - 2,999 19 (30.2%) 14 (25.0%) 33 (27.7%)
3,000 - 9,999 15 (23.8%) 7 (12.5%) 22 (18.5%)
≥ 10,000 - 3 (4.8%) 6 (10.7%) 9 (7.6%)
Unknown or no target number 2 (3.2%) 1 (1.8%) 3 (2.5%)
Total 63 (100%) 56 (100%) 119 (100%)
* Proportions (%) in all responding trials (63 trials) or all not-responded trials (56 trials) are shown.
† Proportions (%) in all trials (119 trials) are shown.
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Questionnaire Parameter Funding source * p-value
†
Public
N=1 4
Private
N=2 9
Combined
N=9
Others
N=1 1
Total
N=6 3
Number of participants N 12 29 9 11 61 0.6296
Mean 1260.6 3301.9 3361.1 1489.4 2582.2
SD 991.9 4311.4 6295.9 1202.5 3910.3
Minimum 861.5 1748 1200 1090 1200
Q1 575 500 800 500 500
Median 2000 4418 2000 2046.5 3000
Q3 300 110 300 300 110
Maximum 3000 20000 20000 4000 20000
Total investigation cost JPY < 10 million(USD < 0.11 million) 0 2 (6.9%) 0 6 (54.5%) 8 (12.7%) 0.0003
JPY 10 - 30 million (USD 0.11 - 0.33 million) 2 (14.3%) 1 (3.4%) 1 (11.1%) 1 (9.1%) 5 (7.9%)
JPY 30 - 100 million (USD 0.33 - 1.09 million) 4 (28.6%) 3 (10.3%) 1 (11.1%) 2 (18.2%) 10 (15.9%)
JPY 100 - 300 million (USD 1.09 - 3.27 million) 7 (50.0%) 10 (34.5%) 1 (11.1%) 1 (9.1%) 19 (30.2%)
JPY 300 million - 1 billion (USD 3.27 - 10.9 million) 0 4 (13.8%) 6 (54.5%) 0 10 (15.9%)
JPY 1 - 3 billion (USD 10.9 - 32.7 million) 0 2 (6.9%) 0 0 2 (3.2%)
JPY ≥ 3 billion (USD ≥ 32.7 million) 0 1 (3.4%) 0 0 1 (1.6%)
Unknown or unspecified 1 (7.1%) 6 (20.7%) 0 1 (9.1%) 8 (12.7%)
Organization responsible for monitoring
‡ Pharmaceutical company 0 6 (20.7%) 1 (11.1%) 1 (9.1%) 8 (12.7%) -
CRO (Contract research organization) 0 5 (17.2%) 2 (22.2%) 0 7 (11.1%)
Academic organization 5 (35.7%) 9 (31.0%) 3 (33.3%) 9 (81.8%) 26 (41.3%)
Others 10 (71.4%) 13 (44.8%) 6 (54.5%) 2 (18.2%) 31 (49.3%)
Organization responsible for data management
‡ Pharmaceutical company 0 6 (20.7%) 1 (11.1%) 0 7 (11.1%) -
CRO (Contract research organization) 1 (7.1%) 8 (27.6%) 0 0 9 (14.3%)
Academic organization 5 (35.7%) 9 (31.0%) 4 (44.4%) 8 (72.7%) 26 (41.3%)
Others 10 (71.4%) 10 (34.5%) 6 (54.5%) 2 (18.2%) 28 (44.4%)
External efficacy evaluation committee Yes 9 (64.3%) 17 (58.6%) 8 (88.9%) 6 (54.5%) 40 (63.5%) 0.5323
No 5 (35.7%) 7 (24.1%) 1 (11.1%) 4 (36.4%) 17 (27.0%)
Unknown or unspecified 0 5 (17.2%) 0 1 (9.1%) 6 (9.5%)
External safety monitoring committee Yes 11 (78.6%) 16 (55.2%) 7 (77.8%) 6 (54.5%) 40 (63.5%) 0.6671
No 3 (21.4%) 9 (31.0%) 2 (22.2%) 4 (36.4%) 18 (28.6%)
Unknown or unspecified 0 4 (13.8%) 0 1 (9.1%) 5 (7.9%)
Biostatistician Yes 11 (78.6%) 21 (72.4%) 7 (77.8%) 6 (54.5%) 45 (71.4%) 0.7010
No 3 (21.4%) 6 (20.7%) 2 (22.2%) 4 (36.4%) 15 (23.8%)
Unknown or unspecified 0 2 (6.9%) 0 1 (9.1%) 3 (4.8%)
Approval of IRB Yes 14 (100%) 26 (89.7%) 9 (100%) 9 (81.8%) 58 (92.1%) 0.4785
No 0 3 (10.9%) 0 1 (9.1%) 4 (6.3%)
Unknown or unspecified 0 0 0 1 (9.1%) 1 (1.6%)
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8Table 2 Results of questionnaire survey (Continued)
Site of registration
‡ University hospital Medical Information Network (UMIN) 7 (50.0%) 8 (27.6%) 5 (55.6%) 4 (36.4%) 24 (38.1%) -
clinicaltrials.gov 7 (50.0%) 7 (24.1%) 4 (44.4%) 3 (27.3%) 21 (33.3%)
Japan Pharmaceutical Information Center (JAPIC) 0 1 (3.4%) 0 0 1 (1.6%)
Japan Medical Association 0 0 0 0 0
Others 1 (7.1%) 2 (6.9%) 0 0 3 (4.8%)
Not registered 3 (21.4%) 13 (44.8%) 3 (33.3%) 4 (36.4%) 23 (36.5%)
Unknown or unspecified 1 (7.1%) 0 0 1 (9.1%) 2 (3.2%)
* Funding sources were categorized based on the answers to questionnaire regarding funding sources;
- Public: Public agency
- Private: Foundation, private organization
- Combined: More than one funding source
- Others: Self-funding, other
† P-values were calculated using Kruskal-Wallis test.
‡ Multiple answers were allowed. Therefore, the sum of all frequencies is not equal to 63 (100%).
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8The number of large-scale clinical trials sorted by the
party responsible for monitoring and data management
activities is shown in Table 2. Twenty-six trials (41.3%)
were conducted by academic organizations, while ‘others’
(such as trial secretariats) were reported most frequently,
with 31 and (49.3%) 28 trials (44.4%) reporting monitoring
and data management activities, respectively. Monitoring
in eight trials (12.7%) and data management in seven trials
(11.1%) were conducted by pharmaceutical companies,
and monitoring of seven trials (11.1%) and data manage-
ment of nine trials (14.3%) were conducted by a contract
research organization (CRO).
Some sponsors commented that a lack of available time
of external and internal staff at the trial sites was one of
the major reasons for delays in subject enrolment.
The numbers of large-scale clinical trials that involved
external committees, biostatisticians and institutional
review boards (IRBs) are shown in Table 2. Forty trials
(63.5%) were associated with external committees to main-
tain objectivity in efficacy evaluations. Forty trials (63.5%)
were associated with external committees to monitor the
safety of the drugs or treatments and/or to avoid harmful
outcomes for subjects. Forty-five trials (71.4%) involved
biostatisticians. Fifty-eight trials (92.1%) were approved by
IRBs.
Clinical trial registry
The number of large-scale clinical trials by site of clinical
trial registry is shown in Table 2. The UMIN and clinical-
trials.gov were the major sites of registration, used for the
registration of 24 trials (38.1%) and 21 (33.3%) trials,
respectively. Only one trial (1.6%) was registered by the
Japan Pharmaceutical Information Center (JAPIC) and
none by the Japan Medical Association. The sponsors of
23 trials (36.5%) responded that the trial was ‘not
registered’.
Discussion
Our examination of the funding of large-scale clinical trials
in cardiovascular and metabolic diseases in Japan revealed
that sponsors of large-scale clinical trials in Japan received
funding from various sources but some of them were una-
ware of their responsibilities in managing and/or financing
the costs of clinical trials. Of the trials funded by founda-
tions, all trials except for those reporting that their funding
source was unknown or unspecified were funded by private
organizations such as pharmaceutical companies, through
these foundations. This finding indicates that there are still
many trials whose funding sources are unclear. Regarding
the infrastructure for operating large-scale clinical trials,
more than half of the trials received support in the form of
human and/or material resources in trials funded by foun-
dations/private organizations. Most of the support from
foundations/private organizations was in the form of
human resources. Some sponsors commented that a lack
of available time of external and internal staff at the trial
sites was one of the major reasons for delays in subject
enrolment. These results suggest that the current situation
should be improved by providing sufficient human
resources for clinical trials. In about one third of the trial,
third parties, such as independent efficacy/safety evaluation
committees and biostatisticians, were not involved. Thus,
there is room for improvement, although these frequencies
are relatively high. One of the limitations of our study was
that some of the large-scale clinical trials in Japan might
have not been included due to lack of publications through
clinical trial registries.
Sample sizes were similar to those reported in a review
of clinical trials in Western countries between 2000 and
2005 [5], where the mean and median numbers of partici-
pants were 560-4,239 and 421-1,486, respectively, although
the number of participants was found to vary between
trials with different funding sources.
Approximately one third of the responding trials were
registered by the UMIN and clinicaltrials.gov, respectively.
These sites for registration were both recommended for
clinical trial registry by the International Committee of
Medical Journal Editors (ICMJE) [16]. Our findings sug-
gest that some sponsors are not aware of the importance
of clinical trial registration. ICMJE in 2004 [12], the
Declaration of Helsinki revised in 2008 [17] and the CON-
SORT declaration in 2010 [18] request the disclosure of
trial protocol summaries and results by sponsors of clinical
trials to avoid publication biases. Considering the purpose
of clinical trial registration, we wish to emphasize that
sponsors should be aware an important responsibility of
sponsors is to minimize publication bias, thus improving
the quality of evidence produced by large-scale clinical
trials.
Evidence from clinical trials using true endpoints such
as cardiovascular events is important, despite the high
costs involved. We found that the currently available evi-
dence was obtained in trials receiving funding from var-
ious sources, and requiring various infrastructural
resources. However, the potential effects of funding
sources on the results of clinical trials represent a major
problem, potentially contributing to lower reliability of
clinical practice guidelines. Previous trials in Western
countries reported that industry-supported meta-analyses
were less transparent than meta-analyses with non-profit
support or no support [5-11]. In 2008, the Association of
American Medical Colleges reported an examination of
the relationship between academic institutions and phar-
maceutical industries, and recommended that discussions
should be undertaken by committees consisting of both
academics and pharmaceutical industry staff to improve
the transparency of clinical trials [19]. The transparency of
clinical trials is important for minimizing potential bias in
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companies. As a first step, we wish to highlight the impor-
tance of revealing funding and infrastructural sources, as
well as the importance of clinical trial registration by spon-
sors and their supporters. In addition, ways of improving
education related to financial bias and publication bias in
medical programs at universities and medical colleges
should be seriously considered.
One limitation of the current study was that we did
not receive responses from the sponsors of approxi-
mately 40% of the trials we initially identified. In addi-
tion, it was not clarified where the money was allocated
in each trial. Therefore, this survey did not allow for
conclusions on whether expensive trials requested the
additional amount of support to recruit more staff, use
more sophisticated methods and high technology
resources, or they had just to pay extra money for hon-
orariums and travel expenses, which probably do not
contribute much to the improvement of the validity of
clinical trials.
Conclusions
The results of the current study revealed that there were
still many trials whose funding sources were unclear and
many sponsors were unaware of their responsibilities in
managing and/or financing the costs of clinical trials. As
such, we propose the establishment of rules regarding
funding and human resource-related support structures, e.
g. requirements for concurrent funding from multiple
sources, clarification of legal requirements, requirements
for thorough disclosure of conflicts of interest, promotion
of internal human resource use and outsourcing, and clari-
fication of the responsibilities of individuals involved in
conducting trials. These results can contribute to the
improvement of conflict-of-interest management in Japan
as well as other countries. This discussion should take
place as soon as possible to facilitate appropriate clinical
trials. After such an improvement, we will be able to inves-
tigate more efficient allocation of various resources to
improve the validity of clinical trials and quality of evi-
dences from clinical trials.
Additional material
Additional file 1: Answer Sheets for Questionnaire Survey
Regarding Executions of Large-Scale Clinical Trials Evaluating
Cardiovascular Events as Endpoint. These answer sheets are the
English translated versions used in our survey. The answer sheets
distributed to sponsors were written in Japanese.
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